API | ligelizumab

ligelizumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Ligelizumab is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It is an anti-IgE that binds to IGHE an acts as an immunomodulator. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
ligelizumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Immunoglobulin heavy constant epsilon (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ligelizumab | qge031 | qge-031

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Asthma (Phase 2)

Chronic Urticaria (Phase 3)

Dermatitis, Atopic (Phase 2)

Food Hypersensitivity (Phase 3)

Hypersensitivity (Phase 1)

Peanut Hypersensitivity (Phase 3)

Pemphigoid, Bullous (Phase 2)

Urticaria (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 20
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue